trial

Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

NCTId NCT00138775
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 200
Sponsored by Sheba Medical Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
200
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-10
Primary completion
—
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
D-serine

Sponsors

Sheba Medical CenterLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Mark Weiser, MDPrincipal Investigator

Sites

14 total
Acre, IsraelAfula, IsraelBat Yam, IsraelBeer-Yaacov, IsraelHod HaSharon, IsraelJerusalem, IsraelJerusalem, IsraelNess Ziona, IsraelPardesiyya, IsraelPetah Tikva, IsraelRamat Gan, IsraelShaar Menashe, Israel

Facts & assertions

3 sourced
Enrollment
200
Phase
PHASE2
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Sheba Medical Center
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Mark Weiser, MD
person